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Coding and long non-coding RNA (lncRNA) metabolism is now revealing its crucial role in Amyotrophic
Lateral Sclerosis (ALS) pathogenesis. In this work, we present a dataset obtained via Illumina RNA-seq
analysis on Peripheral Blood Mononuclear Cells (PBMCs) from sporadic and mutated ALS patients
(mutations in FUS, TARDBP, SOD1 and VCP genes) and healthy controls. This dataset allows the whole-
transcriptome characterization of PBMCs content, both in terms of coding and non-coding RNAs, in order
to compare the disease state to the healthy controls, both for sporadic patients and for mutated patients.
Our dataset is a starting point for the omni-comprehensive analysis of coding and lncRNAs, from an easy to
withdraw, manage and store tissue that shows to be a suitable model for RNA profiling in ALS.
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Background & Summary
Deep sequencing technologies allow high-throughput massive-parallel RNA sequencing, permitting an
extensive characterization of transcriptomic profile of cell populations and tissues. RNA-seq analyses are
the gold standard for in depth characterization of global changes in gene expression levels between
different conditions (e.g.: disease and healthy subjects or treated and untreated samples)1.
Such comprehensive analysis are currently bringing the light on the expression of largely unexplored
RNA classes. While coding RNA involvement in a wide plethora of disorders has been subject of intense
research, the more recently revealed class of lncRNAs is only starting to be characterized. LncRNAs are
RNA transcripts greater than 200 nucleotides that lack an open reading frame and therefore do not
encode proteins2. The heterogeneity of lncRNAs, both in biological type and function, is a major obstacle
that makes it difficult to extract information about lncRNAs function and to enrich our knowledge3.
While coding genes are widely annotated, high-quality catalogues of lncRNAs and information on the
tissues in which they are expressed are recently being constructed4–6. Recent efforts are directed to
characterize this largely unexplored functional component of the genome. Deep sequencing is a precious
instrument to obtain information suitable to investigate both coding and lncRNAs simultaneously in the
same sample, and this comprehensive RNA analysis can elucidate fundamental mechanisms in gene
expression regulation at post-transcriptional level7,8.
There is mounting evidence that altered RNA metabolism, both involving coding and non-coding
RNAs, plays an important role in ALS pathogenesis9–13. ALS is an adult-onset, progressive and fatal
neurodegenerative disease, caused by the selective loss of both upper and lower motor neurons in the
cerebral cortex, brainstem and spinal cord. The pathogenesis of the disease is still unknown. Moreover,
the investigation of ALS mechanism is challenging due to the difficulty to obtain a sufficient amount of
biological material from ALS patients: it is indeed impossible to access biological samples from the most
affected areas, such as spinal cord. PBMCs have been shown to be a convincing and realistic model for
ALS, since many pathways, typically located in neurons, are also activated in these cells8,14,15.
Furthermore, low ALS incidence (ranging between 1 and 2.5/100’000)16 and low percentage of familial
ALS cases (5-10%) impose the requirement of data sharing and data aggregation among different
hospitals and laboratories in order to obtain a sufficient sample size. Detailed curation of these datasets is
paramount for accurate interpretation, widespread dissemination, and repurposing of data.
In this paper, we present a dataset suitable for the analysis for both coding RNAs and lncRNAs in
PBMCs of 15 sporadic ALS (sALS) patients, 9 ALS patients with mutation in classical ALS-genes (SOD1,
FUS, TARDBP and VCP) and 7 healthy controls. More in detail, these data are suitable for antisense
lncRNAs detection and characterization because of the chemistry of the protocol properly design to
maintain strandness information. Strand-specific RNA-Seq permits a more complete understanding of
the transcriptome, enhancing resolution for sense/antisense profiling17.
Part of this dataset was used to perform an analysis of differentially expressed transcripts (coding
RNAs and lncRNAs)8 aiming at investigating the importance of sense and antisense RNA regulation in
central and peripheral systems in ALS disease.
To our knowledge, no dataset of RNA expression in PBMCs from ALS patients is publicly available.
Our dataset is a starting point for the omni-comprehensive analysis of RNA classes, from an easy to
withdraw, manage and store tissue that shows to be a suitable model for RNA profiling in ALS8.
It was shown that in RNA-seq studies, increasing sample size is the best choice to enhance statistical
power18. For these reasons, the re-usability of this dataset is related to the possibility to expand studies
with smaller sample sizes, especially for mutated patients, to identify new sense and antisense transcripts
with altered expression in both sporadic and mutated ALS patients compared to healthy controls and to
provide an open-angle point of view for a broad-spectrum characterization.
Methods
Isolation of human PBMCs from ALS patients and healthy controls
Subject enlistment. 24 ALS patients and 7 age- and sex-matched healthy controls (CTRL) were
recruited after obtaining written informed consent (Table 1). ALS patients underwent clinical and
neurologic examination at IRCCS National Neurological Institute “C. Mondino” (Pavia, Italy). All
patients were diagnosed with ALS as defined by El Escorial criteria. All ALS patients were analysed for
causative mutations in SOD1, TARDBP, FUS, C9orf72, ANG and VCP genes: 15 patients resulted to be
sporadic (sALS) and are indicated as ALS-s1, ALS-s2 and so on. Three patients were mutated in SOD1
gene (SOD1-m1, SOD1-m2 and SOD1-m3), three in FUS gene (FUS-m1, FUS-m2 and FUS-m3), two in
TARDBP gene (TARDBP-m1 and TARDBP-m2) and one in VCP gene (VCP-m1). The seven control
subjects (indicatetd as CTRL1-CTRL7) have been recruited at the Transfusional Service and Centre of
Transplantation Immunology, Foundation San Matteo, IRCCS (Pavia, Italy). All details are reported in
Table 1.
The study protocol to obtain PBMCs from patients and controls was approved by the Ethical
Committee of the National Neurological Institute “C. Mondino”, IRCCS (Pavia, Italy). Before being
enrolled, the subjects participating in the study signed an informed consent form (Protocol n°375/04 –
version 07/01/2004). All experiments were performed in accordance with relevant guidelines and
regulations. These methods and following methods are expanded versions of descriptions in our related
work8.
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Isolation of human PBMCs. PBMCs were prepared by centrifugation. Peripheral blood was layered
(density = 1.077) and centrifuged at 950 g for 30 min. After isolation on a Ficoll-Histopaque layer (Sigma
Aldrich, Italy), cell viability was assayed by a trypan blue exclusion test and cells were then used for RNA
extraction.
RNA extraction. Samples were homogenized and total RNA was isolated by Trizol® reagent (Life
Science Technologies, Italy) following the manufacturer’s protocol. RNAs were quantified using a
Nanodrop ND-100 Spectrophotometer (Nanodrop Technologies, Wilmington, USA) and a 2100
Bioanalyzer (Agilent RNA 6000 Nano Kit, Waldbronn, Germany); RNAs with a 260:280 ratio of ≥1.5
and an RNA integrity number of ≥8 were deep sequenced (Supplementary Figure 1).
RNA-seq library preparation, sequencing and analysis. Sequencing libraries were prepared with the
Illumina TruSeq Stranded RNA Library Prep, version 2, Protocol D, using 500-ng total RNA (Illumina,
USA). The qualities of the libraries were assessed by 2100 Bioanalyzer with a DNA1000 assay. Libraries
were quantified by qPCR using the KAPA Library Quantification kit for Illumina sequencing platforms
(KAPA Biosystems); RNA processing has been carried out using Illumina NextSeq 500 Sequencing, using 8
samples for each run mixing samples and controls in each flowcell to avoid not manageable batch-effects.
Sample GEO Sex Age Age of onset Mutation
CTRL1 GSE106443 M 48 na na
CTRL2 GSE106443 M 60 na na
CTRL3 GSE106443 M 68 na na
CTRL4 GSE115259 M 38 na na
CTRL5 GSE115259 F 36 na na
CTRL6 GSE115259 F 40 na na
CTRL7 GSE115259 F 40 na na
ALS-s1 GSE106443 M 66 65 na
ALS-s2 GSE106443 M 63 61 na
ALS-s3 GSE106443 F 61 60 na
ALS-s4 GSE106443 F 70 68 na
ALS-s5 GSE106443 M 56 55 na
ALS-s6 GSE106443 F 55 53 na
ALS-s7 GSE106443 F 56 55 na
ALS-s8 GSE106443 F 83 73 na
ALS-s9 GSE106443 M 66 60 na
ALS-s10 GSE106443 F 58 58 na
ALS-s11 GSE106443 M 68 65 na
ALS-s12 GSE115259 M 86 84 na
ALS-s13 GSE115259 F 68 65 na
ALS-s15 GSE115259 M 71 70 na
ALS-s16 GSE115259 F 69 67 na
FUS-m1 GSE106443 M 49 48 FUS R521C
FUS-m2 GSE106443 F 50 49 FUS P160R
FUS-m3 GSE115259 M 57 56 FUS G302A
SOD1-m1 GSE106443 M 50 49 SOD1 L106F
SOD1-m2 GSE106443 F 74 73 SOD1 G147S
SOD1-m3 GSE115259 F 58 57 SOD1 G93D
TARDBP-m1 GSE106443 F 52 50 TARDBP A382T
TARDBP-m2 GSE106443 M 68 66 TARDBP G357D
VCP-m1 GSE115259 M 51 50 VCP R191Q
Table 1. RNA-seq profiling to evaluate differential gene expression. All samples had the same source
(blood sample) and were processed with the following steps: PBMCs isolation, RNA extraction and
RNA-seq. All samples included in this study were Italian. All ALS patients had spinal onset and sample
collection was performed after 6 months from exordium.
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FastQ files were generated via llumina bcl2fastq2 (Version 2.17.1.14 - http://support.illumina.com/
downloads/bcl2fastq-conversion-software-v217.html) starting from .bcl files produced by Illumina NextSeq
sequencer (see Table 2).
Quality validation and read mapping
Quality of individual sequences were evaluated using FastQC software (see Code Availability 1) after
adapter trimming with cutadapt software. Per base sequence quality plots, showing the Phred quality score
distribution among all sample reads are shown in Figure 1. Gene and transcript intensities were computed
using STAR/RSEM software19 using the “--strandness forward” option (see Code Availability 2 and 3 and
Figure 2). Human genome reference used for the alignment was GRCh38 (Gencode release 27): in a rapidly
evolving field like the one of non coding RNA analysis it is indeed fundamental to use up-to-date reference
versions containing all the available information about annotated coding and non coding RNAs.
Mapping results are summarized in Table 2. Percentage of uniquely mapped reads is 21.8% on
average, with standard deviation 10.35%. Remaining reads belong to ribosomal RNA because of the non
perfect ribosomal RNA depletion. Since 10 to 25M reads are suggested for RNA-Seq experiments20, this
dataset is suitable for differential expression analysis, since about 60% of samples (21/36) have at least
10 M reads. Furthermore, biological replicates are the most effective strategy to improve statistical power
Sample Number of
input reads
Average input
read length
Uniquely mapped
reads %
Number of reads mapped
to multiple loci
% of reads mapped
to multiple loci
Seq. batch
CTRL1 9.85E + 07 2 × 75 22.68% 5.55E + 07 56.38% 1
CTRL2 8.51E + 07 2 × 75 25.65% 5.49E + 07 64.53% 1
CTRL3 9.00E + 07 2 × 75 26.99% 5.53E + 07 61.47% 2
CTRL4 2.00E + 07 2 × 75 6.50% 1.23E + 07 61.53% 2
CTRL5 2.28E + 08 2 × 75 11.02% 1.71E + 08 74.93% 3
CTRL6 1.05E + 08 2 × 150 4.17% 2.88E + 07 27.54% 4
CTRL7 5.53E + 07 2 × 150 2.96% 1.77E + 07 31.95% 4
ALS-s1 8.30E + 07 2 × 75 26.69% 3.96E + 07 47.72% 1
ALS-s2 9.25E + 07 2 × 75 27.52% 5.73E + 07 61.92% 1
ALS-s3 9.39E + 07 2 × 75 33.88% 5.23E + 07 55.73% 1
ALS-s4 9.10E + 07 2 × 75 37.71% 2.56E + 07 28.17% 1
ALS-s5 9.18E + 07 2 × 75 31.32% 5.51E + 07 60.00% 2
ALS-s6 8.74E + 07 2 × 75 32.43% 5.29E + 07 60.55% 2
ALS-s7 1.03E + 08 2 × 75 17.58% 7.60E + 07 73.79% 2
ALS-s8 7.73E + 07 2 × 75 28.06% 4.71E + 07 60.97% 2
ALS-s9 7.32E + 07 2 × 75 24.14% 3.69E + 07 50.35% 3
ALS-s10 9.12E + 07 2 × 75 14.76% 5.79E + 07 63.49% 3
ALS-s11 7.83E + 07 2 × 75 34.72% 4.48E + 07 57.26% 3
ALS-s12 4.11E + 07 2 × 150 7.12% 2.12E + 07 51.64% 4
ALS-s13 7.17E + 07 2 × 150 17.87% 3.76E + 07 52.36% 4
ALS-s15 5.36E + 07 2 × 150 10.09% 3.52E + 07 65.63% 4
ALS-s16 8.36E + 07 2 × 150 7.68% 5.53E + 07 66.15% 4
FUS-m1 9.63E + 07 2 × 150 22.49% 6.84E + 07 71.03% 4
FUS-m2 9.82E + 07 2 × 75 13.62% 7.33E + 07 74.65% 2
FUS-m3 1.65E + 06 2 × 150 10.43% 1.28E + 07 81.24% 4
SOD1-m1 1.14E + 08 2 × 75 28.38% 6.86E + 07 60.15% 3
SOD1-m2 8.50E + 07 2 × 75 31.92% 4.88E + 07 57.46% 1
SOD1-m3 3.51E + 07 2 × 75 22.36% 2.33E + 07 66.42% 3
TARDBP-
m1
1.16E + 08 2 × 75 31.21% 6.21E + 07 53.46% 3
TARDBP-
m2
7.94E + 07 2 × 75 29.40% 3.50E + 07 44.14% 3
VCP-m1 2.98E + 07 2 × 75 13.46% 2.07E + 07 69.66% 1
Table 2. RNA-seq read statistics. All RNA samples used to perform RNA-Seq analaysis had RIN = 8
and 260/280 ratio 1.5, as recommended in manufacturer’s protocol.
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Figure 1. Quality assessment FASTQ data. Quality assessment of raw FASTQ sequence data for paired end and
left (sample_name_R1) and right reads (sample_name_R2). Box and whisker plots demonstrate the distribution of
per base quality for each left and right read position read for each of the analyzed samples. Mean value is indicated
by the blue line and the yellow box represents the interquartile range (25–75%) with the lower and upper whiskers
represent the 10 and 90% points, respectively. Plots were generated by FastQC program (see Code Availability 1).
www.nature.com/sdata/
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in such experiments. For this reason, we decided to share our dataset with the scientific community, to
have the possibility of integrating our data with similar data obtained in different laboratories.
Expressed transcripts per sample were evaluated imposing a minimum threshold of 5 counts per gene
to consider it as expressed. Figure 3 shows the amount of coding and non coding transcripts detected in
each sample. With the exception of 4 samples which have a low number of detected transcripts (probably
due to a lower number of available reads), 7000 to 14000 expressed coding genes and 500 to 3000 non
coding genes were detected per sample. This is in accordance with the currently available knowledge
about non coding transcripts that result to be globally less ex-pressed than coding ones within the cell21.
Downstream analysis
Differential expression analysis for all transcripts (coding and non coding RNAs) was performed with the
R package DESeq222 (see Code Availability 4). This tool was selected because of its superior performance
in identifying isoforms differential expression23.
RNA extraCTRLtion
from PBMCTRL
RNA quality assessment
RNASeq
(Illumina NextSeq500)
Raw reads
(fastQ format)
ReferenCTRLe Genome
Alignment (STAR)
StatistiCTRLs
CTRLomputation
Differential Expression
Analysis (DESeq2)
QCTRL reports
GRCTRLh38 
(GENCTRLODE27)
Visualization, data
exploration,
etCTRL (R)
Figure 2. Experimental overiview and evaluation of sample variance. (a) The flowchart represents RNA-Seq
workflow and data analysis. (b) An estimate of the dispersion parameter for each gene is shown. (c) Principal
component analysis results. (d) Heatmap showing the sample-to-sample distance. It was obtained with DeSeq2
package on regularized-logarithm transformed counts. Color code is reported above the heatmap.
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Genes were considered differentially expressed and retained for further analysis with |log2(disease
sample/healthy control)| ≥ 1 and a FDR ≤ 0.1. Analysis workflow is summarized in Figure 2.
For each sample, we evaluated the number of detected transcripts for coding and lncRNAs, separately.
Transcripts were considered if covered by at least 5 reads24. Results are summarized in Figure 3.
Code availability
The following software and versions were used for quality control and data analysis as described in the
main text:
1. FastQC v0.11.6 was used for quality assessment of raw FASTQ sequencing data: http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/
2. STAR 2.6 was used for reads mapping to the human GRCh38 genome assembly: https://github.com/
alexdobin/STAR/releases
3. RSEM v1.3.0, was used for gene expression quantification: http://bioinf.wehi.edu.au/featureCounts/
4. DESeq2 v1.20.0 was used for differential gene expression analysis: http://bioconductor.org/packages/
DESeq2
Data Records
Raw FASTQ files for the RNA-seq libraries were deposited to the NCBI Sequence Read Archive (SRA), and
have been assigned BioProject accession PRJNA416880, Table 1, (Data Citation 1) and BioProject accession
PRJNA474387, Table 1 (Data Citation 2). Raw counts data were deposited to the NCBI Gene Expression
Omnibus (GEO) with accession number GSE106443, Table 1 (Data Citation 3) and GSE115259, Table 1
(Data Citation 4). First dataset has SRA SRP123453, second dataset has SRA SRP149638.
Technical Validation
RNA integrity assessment
RNAs were quantified using a Nanodrop ND-100 Spectrophotometer (Nanodrop Technologies,
Wilmington, USA) and a 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit, Waldbronn, Germany); RNAs
with a 260:280 ratio of ≥1.5 and an RNA integrity number of ≥8 were subjected to deep sequencing.
RNA-seq data qyality assessment
We applied FastQC v0.11.5 software to verify that per base quality scores are suitable for downstream
analysis (Figure 1). Mapping percentage have been computed and are reported in Table 2. PCA plot,
distance matrix and dispersion estimates are also shown in Figure 2.
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